Desai Darshi, Desai Aditya, Jamil Aneeque, Csendes Denise, Gutlapalli Sai D, Prakash Keerthana, Swarnakari Kiran M, Bai Meena, Manoharan Mohana P, Raja Rabab, Khan Safeera
Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Internal Medicine, University of California Riverside School of Medicine, St. Bernardine's Medical Center, San Bernardino, USA.
Cureus. 2023 Feb 12;15(2):e34902. doi: 10.7759/cureus.34902. eCollection 2023 Feb.
Heart failure (HF) contributes to the cardiovascular health burden worldwide. Patients with heart failure have been recently studied to possess unique changes in the gut microbiome that affect immune homeostasis and metabolism. In this systematic review of the literature, we aim to identify the impact of gut dysbiosis on heart failure. We used Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines to conduct our systematic review. We searched the literature on databases such as PubMed, PubMed Central (PMC), Medline, and ScienceDirect. Ten articles were included for review. There were significant differences in the gut microbiome composition in heart failure. Relative abundance of and relative depletion of , and The composition varied according to age, heart failure stage, and decompensation level. The composition remained unaltered with ejection fraction. There was an increased expression of genes responsible for the metabolism of amino acids, carbohydrates, choline trimethylamine-lyase (TMA-lyase), lipopolysaccharide (LPS) biosynthesis, tryptophan, and lipid metabolism. The resultant changes affected the levels of metabolites, such as trimethylamine N-oxide (TMAO), indoxyl sulfate (IS), and LPS, and inflammatory markers in the feces and plasma, which contributed to heart failure. These biomarkers of heart failure could serve as targets for the prevention and treatment of heart failure. Patients with heart failure harbor a unique constellation of gut microbiota that affect the pathogenesis of heart failure. Further studies are needed to understand the causal relationship between dysbiosis and heart failure.
心力衰竭（HF）是全球心血管健康负担的一个因素。最近的研究发现，心力衰竭患者的肠道微生物群存在独特变化，这些变化会影响免疫稳态和新陈代谢。在这项文献系统综述中，我们旨在确定肠道微生物群失调对心力衰竭的影响。我们使用系统评价和荟萃分析的首选报告项目（PRISMA）2020指南进行系统综述。我们在PubMed、PubMed Central（PMC）、Medline和ScienceDirect等数据库中检索文献。纳入了10篇文章进行综述。心力衰竭患者的肠道微生物群组成存在显著差异。[具体微生物名称1]的相对丰度以及[具体微生物名称2]、[具体微生物名称3]和[具体微生物名称4]的相对减少。其组成因年龄、心力衰竭阶段和失代偿程度而异。其组成与射血分数无关。负责氨基酸、碳水化合物、胆碱三甲胺裂解酶（TMA裂解酶）、脂多糖（LPS）生物合成、色氨酸和脂质代谢的基因表达增加。这些变化影响了粪便和血浆中的代谢产物水平，如氧化三甲胺（TMAO）、硫酸吲哚酚（IS）和LPS，以及炎症标志物，这些都导致了心力衰竭。这些心力衰竭的生物标志物可作为心力衰竭预防和治疗的靶点。心力衰竭患者拥有独特的肠道微生物群，这些微生物群会影响心力衰竭的发病机制。需要进一步研究以了解微生物群失调与心力衰竭之间的因果关系。
